New BCMA-Directed Therapies Show Promise in Multiple Myeloma
Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma
Chemo-Free Regimen for Ph+ ALL Yields High Rate of Deep MRD Negativity
Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma
The Lifesaving Legacy of Vaccines
Health of Myeloma Patient's Marriage Tied to Recovery After Transplant
Optimizing Sequencing of BCMA-Directed Therapies in Myeloma
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
Advances in ALL at ASH Meeting Include New Blinatumomab Data and More
The Forgotten Toll of Polio
Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma
Benefits of Drug Combo in Myeloma Maintenance Shown in Relevant Subgroups
Pain, Fatigue Benefits May Give Resistance Training a Leg Up in Multiple Myeloma
Masking Policies Show Clear Impact on Hospital-Onset Respiratory Infections
Are GLP-1 Drug Holidays a Risk Worth Taking?
Fostamatinib Fails to Improve Outcomes in Hypoxemic COVID Patients
Untangling GLP-1 Risks: Are Side Effects Overblown?
GLP-1s: The Medications Redefining Diabetes and Obesity Treatment
Modified Donanemab Dosing May Reduce ARIA-E Risk in Early Alzheimer's
Novel Therapies for Asthma in the Pipeline
AREDS2 Supplements and Geographic Atrophy Progression
International Working Group Discusses Diagnosing Alzheimer's Disease
Barzolvolimab Shows Promise for Cold Urticaria and Dermographism
AREDS Supplements May Slow Geographic Atrophy Progression Toward the Fovea
